Wednesday, December 02, 2020 2:17:46 PM
CRO has been working hard for over a month:
Nov 2 PR
"Contract Research Organizations have been secured to expedite trial enrollment with many clinical sites expressing interest in participating in the study. The Company anticipates commencing the Brilacidin for COVID-19 clinical trial in 4Q2020."
July 7 PR
"Steps have begun with the Contract Development and Manufacturing Organization (CDMO) in preparation for upcoming manufacture of the drug product for COVID-19 clinical trial use, to be followed by interactions with relevant Health Authorities to obtain input and guidance on trial design.”
Nov 16 PR
"Sufficient Brilacidin intravenous (IV) drug product has been manufactured to complete this trial, and potentially future COVID-19 trials, providing the Company with added flexibility as it develops Brilacidin for the treatment of COVID-19."
Aug 26 news release
https://www.globenewswire.com/news-release/2020/08/26/2084130/0/en/Dr-William-F-DeGrado-a-Discoverer-of-Brilacidin-Joins-Innovation-Pharmaceuticals-as-Scientific-Advisor.html
" “I am excited to be involved again with Brilacidin, a unique biomimetic drug candidate that has been properly advanced clinically by Innovation across multiple indications,” said William F. DeGrado, PhD, Professor in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF). “I look forward to collaborating with the Innovation team—most urgently, toward developing Brilacidin as a promising therapeutic to treat the novel coronavirus and possibly other viruses. Brilacidin already has exhibited intriguing anti-SARS-CoV-2 in vitro inhibitory efficacy at clinically-achievable concentrations based on Brilacidin pharmacokinetics seen in earlier clinical testing. The world is in dire need of new antiviral treatments and Brilacidin is well-positioned potentially to emerge as one.”
That is a lot of positive news in just a few months,isn't it?
GLTA Farrell
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM